Conatus Pharmaceuticals (CNAT) Misses Q3 EPS by 8c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q3 EPS of ($0.13), $0.08 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $9.6 million versus the consensus estimate of $16.06 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Piper Sandler Reiterates Overweight Rating on Patterson-UTI Energy (PTEN)
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance